Activating mitofusins interrupts mitochondrial degeneration and delays disease progression in SOD1 mutant amyotrophic lateral sclerosis
Human Molecular Genetics · 2023
DOI: 10.1093/hmg/ddac287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2023. Verfasst von Xiawei Dang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Washington University School of Medicine, St. Louis MO USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NINDS NIH HHS, Muscular Dystrophy Association.
Abstract (Originalsprache)
Mitochondrial involvement in neurodegenerative diseases is widespread and multifactorial. Targeting mitochondrial pathology is therefore of interest. The recent development of bioactive molecules that modulate mitochondrial dynamics (fusion, fission and motility) offers a new therapeutic approach for neurodegenerative diseases with either indirect or direct mitochondrial involvement. Here, we asked: (1) Can enhanced mitochondrial fusion and motility improve secondary mitochondrial pathology in superoxide dismutase1 (SOD1) mutant amyotrophic lateral sclerosis (ALS)? And: (2) What is the impact of enhancing mitochondria fitness on in vivo manifestations of SOD1 mutant ALS? We observed that small molecule mitofusin activators corrected mitochondrial fragmentation, depolarization and dysmotility in genetically diverse ALS patient reprogrammed motor neurons and fibroblasts, and in motor neurons, sensory neurons and fibroblasts from SOD1 G93A mice. Continuous, but not intermittent, pharmacologic mitofusin activation delayed phenotype progression and lethality in SOD1 G93A mice, reducing neuron loss and improving neuromuscular connectivity. Mechanistically, mitofusin activation increased mitochondrial motility, fitness and residency within neuromuscular synapses; reduced mitochondrial reactive oxygen species production; and diminished apoptosis in SOD1 mutant neurons. These benefits were accompanied by improved mitochondrial respiratory coupling, despite characteristic SOD1 mutant ALS-associated downregulation of mitochondrial respiratory complexes. Targeting mitochondrial dysdynamism is a promising approach to alleviate pathology caused by secondary mitochondrial dysfunction in some neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Washington University School of Medicine, St. Louis MO USA.
- Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi 710061, China.
ORCID-Profile: Xiawei Dang
Förderung
- NHLBI NIH HHS
- NINDS NIH HHS
- Muscular Dystrophy Association
- China Scholarship Council
- National Institutes of Health
Zitieren
APA
Dang, X., Zhang, L., Franco, A., & Dorn Ii, G. W. (2023). Activating mitofusins interrupts mitochondrial degeneration and delays disease progression in SOD1 mutant amyotrophic lateral sclerosis. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddac287
Vancouver
Dang X, Zhang L, Franco A, Dorn Ii GW. Activating mitofusins interrupts mitochondrial degeneration and delays disease progression in SOD1 mutant amyotrophic lateral sclerosis. Human Molecular Genetics. 2023. doi:10.1093/hmg/ddac287
BibTeX
@article{Dang2023,
author = {Dang, Xiawei and Zhang, Lihong and Franco, Antonietta and Dorn Ii, Gerald W},
title = {Activating mitofusins interrupts mitochondrial degeneration and delays disease progression in SOD1 mutant amyotrophic lateral sclerosis},
journal = {Human Molecular Genetics},
year = {2023},
doi = {10.1093/hmg/ddac287}
}
EUVIMED